The licensing agreement is for two promising metabolites with
the potential to significantly improve metabolic health and
naturally address the obesity epidemic by filling a crucial void
left by GLP-1 drugs.
DOVER,
Del., July 30, 2024 /PRNewswire/
-- Metabolize, a breakthrough solution to naturally address
obesity, announced today that the company licensed two metabolites
aimed at solving obesity in an exclusive worldwide licensing
agreement from Stanford University's
Office of Technology Licensing (OTL). The new licensing agreement
enables Metabolize to apply cutting-edge research from the lab of
Dr. Jonathan Long, Assoc. Prof. of Pathology and ChEM-H
Institute Scholar at Stanford. The
agreement will enable Metabolize to develop and market these
compounds as Nutraceuticals to offer an effective, affordable,
side-effect-free solution for weight loss.
The agreement comes as Americans shoulder skyrocketing costs,
reaching $1.4T annually, and obesity
numbers continue to rise globally - impacting nearly three billion
people and reducing life expectancy by almost a decade. While GLP-1
drugs have proven to be effective in fighting the global epidemic,
they come with staggering costs and burdensome side effects such as
Anhedonia (diminished interest in pleasure-seeking), nausea,
vomiting, and other gastrointestinal issues, leading 81% to stop
treatment within the first year with many regaining the weight they
lost.
Beyond weight loss, the new compounds will unlock all the
benefits of healthy body weight, including glucose regulation and
increased health span, at a fraction of the cost of GLP-1 drugs.
Metabolize's offering can also be taken as an effective
complementary regimen, which may further accelerate the weight loss
of GLP-1 drugs by targeting different pathways. Initial studies
also indicate that the compounds may also offer a slew of longevity
benefits.
To date, the research underlying the metabolites licensed by
Metabolize has been published in leading academic journals such
as Nature and Cell Metabolism,
outlining groundbreaking potential. Dr. Morris Laster, an experienced biomedical
entrepreneur and investor, will serve as the company's Founder
& CEO, while Gideon Meir,
formerly a senior executive at Standard Industries, will serve as
the company's COO.
"Having led over 40 MedTech investments and founding several
publicly traded biotech companies, I've seen plenty of innovative
ideas with major market potential," said Metabolize CEO
Morris Laster. "Metabolize is not
just at the very top of that list in terms of potential but also
regarding the tech, team, and the gap we're filling in the market
at a crucial time. I'm excited to continue this journey and can't
wait to see the changes in store for countless individuals and the
market."
About Metabolize:
Metabolize is a new natural, side-effect-free, and affordable
solution to effectively address obesity, manage glucose levels, and
tap into anti-aging benefits. The offering constitutes a more
affordable alternative to GLP-1 drugs without side effects and can
be used to augment the weight loss of GLP-1 users by utilizing
different pathways. Metabolize harnesses the power of metabolite
that have already earned recognition in top publications such as
Nature and Cell Metabolism. Currently, the company is in the
process of generating data to apply for the FDA "New Dietary
Ingredient" classification.
For more information visit: https://metabolize.life/
Contact:
Gideon Meir
gideon@metabolize.life
View original
content:https://www.prnewswire.com/news-releases/metabolize-licenses-two-proprietary-metabolites-to-address-obesity-from-stanford-otl-302210129.html
SOURCE Metabolize